2009 Annual Meeting Late Breaking Abstract Preparation Guidelines
All Late Breaking Abstracts must be submitted via the AAAAI online abstract submission site.
Late Breaking Abstracts Submission Site Opens: November 13, 2008
Submission Deadline: December 1, 2008, 11:59pm CST
All authors must follow these AAAAI policies and guidelines in order for their Late Breaking abstract to be reviewed and considered for acceptance for presentation at the 2009 Annual Meeting
Please read carefully
AAAAI Late Breaking Abstract Submission
Policies and Procedures
AAAAI Late Breaking Abstract Submission and Preparation Policies
- Late breaking abstracts MUST be of high quality, represent an important research advance and present information that was not available at the time of regular abstract submission.
- These abstracts must present information that is significant to clinical, translational or basic science, novel, uses appropriate study design, analytical methods and statistical methods and is clearly and logically written.
- Submitters will be required to explain why their abstract is important or late breaking.
- Abstracts submitted only because they missed the initial deadline for regular abstracts will not be considered.
- Late Breaking Abstracts are competitively reviewed.
1.1) Submission Deadline.
Please review the content of your abstract for accuracy. It is the responsibility of the primary author to ensure accuracy of content.
Late breaking abstracts must be received by December 1, 2008 in their final form. This includes the author listing. No abstracts or abstract changes, including author additions or listing order will be accepted after this date.
1.2) Previous Presentations of Abstracts.
Only original abstracts will be accepted.
Abstracts previously accepted and published by other organizations/societies will not be accepted.
1.3) Late Breaking Abstract Authors.
Late breaking abstracts may be submitted by fellows, members and non members of the AAAAI.
An individual may be the first and submitting author of only one late breaking abstract at the 2009 AAAAI Annual Meeting.
Those individuals listed as first authors on regular abstracts are allowed to submit a late breaking abstract.
Sponsorship or co-authorship of additional abstracts is permitted.
1.4) Late Breaking Abstract Preparation.
If accepted for presentation, the first and submitting author is the individual who must present the late breaking abstract. Please be sure that contact information is accurate.
An individual may present only one late breaking abstract at the 2009 AAAAI Annual Meeting.
A speaker who is invited to present at a plenary, symposium, dinner symposium, year-in-review session, course, workshop or seminar does not lose the privilege of presenting a late breaking abstract, provided that an abstract is neither submitted nor required for the invited presentation and that each presentation is substantially and recognizably different from the other in concept and data.
1.5) Duplicate Abstracts.
In an effort to reduce the amount of duplicate abstracts submitted, only one late breaking abstract per clinical study will be allowed from any one laboratory, institution, or group of investigators. Late breaking abstracts summarizing significantly different aspects and presenting significantly different conclusions using the same study population will be allowed, but multiple abstracts focusing on the same or slightly different aspects of the same study are prohibited.
1.6) Tracks and Keywords.
Each late breaking abstract must be submitted within one track and up to three keywords, chosen by the first and submitting author. This information will be used to assist in the systematic review and organization of abstracts and their subsequent presentations. Abstract submitters should provide the appropriate notations on the online submission form. Late breaking abstracts submitted without this information will not be reviewed for presentation at the 2009 AAAAI Annual Meeting. The two tracks are:
- CLINICAL/ TRANSLATIONAL: abstracts that deal predominantly with topics related to in vivo studies of human patients or that present a "bench to bedside" approach, combining both clinical and basic topics in approximately equal amounts
- BASIC: abstracts related to bench research such as in vitro studies of cells, tissues, genes, signaling pathways, allergens, etc., OR with topics in in vivo animal models of disease (minimal human in vivo studies).
1.7) Funding.
The source of funding of the research summarized in the late breaking abstract must be disclosed at the time of submission. Late breaking abstract submitters must provide this information in the appropriate section of the online submission form.
1.8) Late breaking abstract Withdrawals and Revisions
Withdrawals must be received in writing at the AAAAI executive office by January 2, 2009.
Please review your submission carefully. The AAAAI will not accept author additions, new data, or changes to the text of the abstract or author block after December 1, 2008.
It is the responsibility of the presenting author to ensure accuracy of content, spelling and author block (including listing order). Abstracts are directly extracted from the submission database. Late breaking abstracts will be published in the The Journal of Allergy and Clinical Immunology (JACI) exactly as submitted.
All late breaking abstracts presented at the 2009 Annual Meeting will be published in a later edition of The Journal of Allergy and Clinical Immunology, and become the property of the journal publisher. Ownership of submitted abstracts not accepted for presentation reverts to the author.
Be sure all appropriate data and all authors are listed and they are in the correct order.
Organization of Abstract Body
2.1) The organization of the abstract should include the following specification:
- Rationale
A statement of purpose of the study (preferably one sentence).
- Methods
A brief statement of the methods used. For abstracts reporting clinical research, a sentence or phrase presenting the most important selection criteria for subjects should be included.
- Results
A summary of the results presented in sufficient detail with statistical analysis to support the conclusions.
- Conclusions
A statement of the conclusions reached. It is not satisfactory to state, "the results will be discussed," or "other data will be presented," etc.
Be sure to use the words Rationale, Methods, Results and Conclusions in the body of your abstract to indicate the start of each new section. These words will not be included in the overall word count of the abstract. See the Sample Abstract for an example.
2.2) Abstract Length
The maximum length of a late breaking abstract submitted for presentation at the 2008 Annual Meeting is 250 words. Use of the words "Rationale, Methods, Results and Conclusions" as described above will not count towards the 250 word total.
2.3) Tables and graphs are not permitted.
2.4) Title
Capitalize only the first letter of each word of the title.
2.5) Abbreviations
The use of standard abbreviations is desirable (i.e., rbc, kg, mg). A special or unusual abbreviation should be placed in parentheses after the first appearance of the full word for which it represents. Do not use periods after abbreviations or initials. Numerals rather than words should indicate numbers, except to begin sentences.
2.6) Drug Names
Each time a proprietary drug name is used in the abstract, the first letter is capitalized. Non proprietary (generic) names are preferred and are not capitalized.
2.7) Format
You may use your word processor's capabilities for bold, underline, italic, subscript and superscript, or use the tools provided when entering your abstract. Bold the words Rationale, Methods, Results and Conclusions used to separate one section of the abstract from another. Text that will be italic in published form (e.g., genus, species) may be formatted as italics.
2.8) Revisions
You may come back to the site and edit your abstract until the December 1st deadline. After December 1st, no revisions will be allowed.
If accepted for presentation, Late Breaking Abstracts will appear in the supplement exactly as submitted, no revisions will be allowed, and authors cannot be added after December 1, 2008.
Sample Abstract
- Cytokines Enhance Epithelial Cell (EC) Damage Caused by Rhinovirus
- DM Galagan1, MK Schroth1, ED Dick1, WW Busse1, JE Gern1, UW Hospital and
Clinics, Madison, WI
- Rationale: Since the major group rhinovirus (RV) receptor, ICAM 1, is inducible with cytokines that may be present in the allergic airway, we examined the separate and combined effects on V and TNF-a on EC viability in vitro.
Methods: EC isolated from nasal polyp tissue were incubated with either serum free medium or TNF-a (10U/ml). After 24 hours, EC were inoculated with RV49 (106TCID50/ml), a minor group RV which binds to the low density lipoprotein receptor, RV16.
Results: Pre incubating cells with TNF-a before RV inoculation produced additive epithelial cell damage compared to RV inoculation alone (n=3 experiments) (p=0.05).
Conclusions: Thus patients with pre existing airway allergic inflammation may develop increased epithelial cell damage following RV infection.
- = Title
- = Author Block; 1st Author is the primary/submitting author. It is assumed this is whose contact information is provided for notification
- = Abstract Body; 250 word count, not including author, abstract title, author block, and the words: Rational, Methods, Results and Conclusion
Submission Fee
Each late breaking abstract submission must be accompanied by a $50 processing fee. Payment must be made by credit card. Complete the credit card information on the online submission form. Late breaking abstracts received without payment will not be reviewed for presentation at the 2009 AAAAI Annual Meeting.
The fee is not refundable, even if the abstract is not accepted.
Notification of Programming
If the late breaking abstract is accepted for presentation at the 2009 AAAAI Annual Meeting, the first and submitting author will be notified via email by approximately December 29, 2008.
Only the submitting author will be notified of abstract programming. Please make sure all contact information is accurate. Such notification will include: (1) Title of session for abstract presentation and (2) Date and time of session. Late Breaking abstracts scheduled for presentation will be grouped by track, numbered and listed in the program and published in the JACI.
Under no circumstances will changes be made to this schedule.
Abstract Submission Disclosure Policy
Pursuant to the Code of Ethics for the American Academy of Allergy, Asthma and Immunology (AAAAI) and the Standards for Commercial Support of Continuing Medical Education of the Accreditation Council for Continuing Medical Education, the AAAAI requires disclosure of certain information from abstract presenters at the 2008 AAAAI Annual Meeting. A completed form must be received in order for your abstract to be considered for presentation. All abstracts are to be scientifically objective to conform to the generally accepted standards of experimental design, data collection and analysis. Financial and organizational relationships need to be disclosed from the following types of individuals:
- Leaders (officers, Board members, JACI editors, committee chairs/members, and senior staff);
- Faculty for scientific meetings and conferences (planning committee members, moderators, and speakers);
- Participants (at business/committee meetings or other member forums, including involvement in public discourse at scientific meetings and conferences); and
- Authors of AAAAI position statements.
Disclosure by Leaders must be made in writing through use of an official AAAAI Disclosure Form or via the Online Disclosure Management System. A completed form must be returned prior to the commencement of a Leader's term of office. Such disclosure must be updated whenever circumstances require or once per calendar year, whichever is sooner.
Disclosure by Faculty must be made in writing through use of an official AAAAI Disclosure Form or via the Online Disclosure Management System. A completed form must be returned prior to the beginning of the Faculty member's involvement in planning or, if a speaker, before his/her presentation at an AAAAI-sponsored educational activity. Such disclosure must be updated whenever circumstances require or once per calendar year, whichever is sooner. Further, speakers are to disclose to the AAAAI in advance any support they receive or plan to receive in the formulation and development of their presentation. Such support must be approved in advance by the AAAAI.
Faculty who are also speakers must also disclose verbally and visually at the beginning of each presentation. This should be done by the use of a slide or slides, when possible, containing the information on the disclosure form. Speakers are also required to disclose to participants discussion of investigational products or investigational uses of products included in their presentations.
Disclosure by Participants must be made verbally at the time a Participant begins speaking at each business/committee meeting or other member forum they attend. Participants are required to disclose their job title and employer, and any other interest of theirs that would be judged by a majority of their peers to be more than casual and/or likely to impact their ability to exercise independent judgment in addressing the issue being discussed.
Disclosure by Authors must be made in writing through use of the Disclosure Form or via the Online Disclosure Management System. A completed form must be returned prior to the author beginning work on an AAAAI position statement.
Examples of interests that should be disclosed include, but are not limited to, remuneration received by the individual for any activities performed (such as grants, honoraria, legal or medical consulting fees, etc.), research funding sources, investments, gifts, and organizational affiliations. If the individual's employer receives remuneration from a commercial interest* for the individual's activities, this relationship should also be disclosed. Failure to knowingly disclose potential conflicts is a violation of the AAAAI's Code of Ethics and such infringements will be dealt with as detailed in section III.B of the Code of Ethics.
All information disclosed will be reviewed to identify conflicts of interest and to guide the resolution of those conflicts. For Leaders, reviews will be completed by an appropriate AAAAI committee or executive body. For Faculty, reviews will be completed by the Continuing Medical Education Committee or the Annual Meeting Program Committee, depending on the activity in which the faculty member will potentially be involved. For Authors, reviews will be completed by the Practice Diagnostics and Therapeutics Committee.
In all cases, an individual's disclosure will be reviewed in the context of the activity in which s/he will potentially be participating. If a conflict of interest is identified, the reviewers will be asked to identify an appropriate mechanism for resolving the conflict. This could potentially include asking the individual to alter the relationship which creates the conflict, or removing the individual from involvement in the activity. The results of each review will be communicated to the individual and the organization planning the activity to facilitate the resolution of the conflict.
*A commercial interest is defined as any proprietary entity producing health care goods or services consumed by, or used on, patients.
At the time of the abstract submission, all abstract authors are required to disclose all relationships that meet the following parameters:
A. EMPLOYMENT: Name of employer and job title.
B. FINANCIAL INTERESTS: All organizations and commercial interests, other than my employer, from which the abstract author or a member of his/her immediate family or household has received any amount of remuneration in the past 12 months (including grants, honoraria, consulting fees, expert witness or other legal consultation services, etc.) or invest money which may create or be perceived as a conflict of interest. This includes any services that are performed, which generate remuneration for or through their employer. In the case of expert witness/legal consultation services, indicate the topic/issue for which you provided service and for whom the services were rendered (such as plaintiff or defendant).
C. RESEARCH INTERESTS: All organizations which support research projects for which you or a member of your immediate family or household serve as an investigator or co-investigator.
D. ORGANIZATIONAL INTERESTS: All organizations, other than the AAAAI, for which you hold volunteer positions.
E. GIFTS: All organizations from which you or a member of your immediate family or household have received a gift valued at any amount that may create or be perceived as a conflict of interest in the past 12 months.
F. OTHER INTERESTS: All interests of the abstract author or a member of his/her immediate family or household that would be judged by a majority of peers to be more than casual and/or likely to impact the ability to exercise independent judgment. This includes any financial interest in or relationship with any manufacturer of a commercial product, and any financial interest in or relationship with any organization that provides commercial support to AAAAI-sponsored educational activities.
At the time of abstract presentation, abstract presenters are required to verbally disclose the information contained on their online disclosure form which is relevant to their presentation. Abstract presenters are also required to disclose at the time of presentation discussion of investigational products or investigational uses of products included in their presentations.
Informed Consent
Any studies involving human subjects must conform to the principles of the Declaration of Helsinki of the World Medical Association (Clinical Research 1966; 14:103) and must meet all the requirements governing informed consent of the country in which the research was performed. Late breaking abstract submitters must confirm that such procedures were followed at the time of submission by making the appropriate affirmation on the online submission form. Late breaking abstracts whose submitters do not provide the appropriate notation will not be allowed to submit an abstract for the 2007 AAAAI Annual Meeting.
Use of Animals
All studies involving the use of animals must comply with the 1991 revision of "Guiding Principles in the Care and Use of Animals" (American Physiological Association, Bethesda, MD 20814 3991).
All abstracts submitted to the AAAAI are peer reviewed by the AAAAI abstract review subcommittee made up of representatives of the AAAAI Annual Meeting Executive Council and Annual Meeting Program Committee.
 
<back>
| 
